Evaluation of 3′-azido-3′-deoxythymidine, morphine, and codeine as probe substrates for udp-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: Specificity and influence of the UGT2B7*2 polymorphism

Drug Metabolism and Disposition

Volumn 31, Issue 9, 2003, Pages 1125-1133

  Court, Michael H ^a,c   Krishnaswamy, Soundarajan ^a   Hao, Qin ^a   Duan, Su X ^a   Patten, Christopher J ^b   Von Moltke, Lisa L ^a   Greenblatt, David J ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Gentest Corporation   (United States)

^c TUFTS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CODEINE; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 2B7; MORPHINE; MORPHINE 3 GLUCURONIDE; MORPHINE 6 GLUCURONIDE; PROTEIN; UGT 2B4 PROTEIN; UNCLASSIFIED DRUG; ZIDOVUDINE; GLUCURONIDE; UDP GLUCURONOSYLTRANSFERASE, UGT2B7; UDP-GLUCURONOSYLTRANSFERASE, UGT2B7;

ARTICLE; CONTROLLED STUDY; DRUG GLUCURONIDATION; ENZYME KINETICS; ENZYME MECHANISM; ENZYME SPECIFICITY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER MICROSOME; PRIORITY JOURNAL; COMPARATIVE STUDY; ENZYMOLOGY; GENETICS; IN VITRO STUDY; METABOLISM;

CODEINE; GENOTYPE; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; MICROSOMES, LIVER; MORPHINE; POLYMORPHISM, GENETIC; SUBSTRATE SPECIFICITY; ZIDOVUDINE;

EID: 0042858542     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.31.9.1125     Document Type: Article

References (33)

1. Barbier O, Turgeon D, Girard C, Green MD, Tephly TR, Hum DW, and Belanger A (2000) 3′-Azido-3′-deoxythimidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7). Drug Metab Dispos 28:497-502.
2. Bhasker CR, McKinnon W, Stone A, Lo AC, Kubota T, Ishizaki T, and Miners JO (2000) Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2BT) at amino acid 268: ethnic diversity of alleles and potential clinical significance. Pharmacogenetics 10:679-685.
3. Boase S and Miners JO (2002) In vitro-in vivo correlations for drugs eliminated by glucuronidation: investigations with the model substrate zidovudine. Br J Clin Pharmacol 54:493-503.
4. Cepeda MS, Farrar JT, Roa JH, Boston R, Meng QC, Ruiz F, Carr DB, and Strom BL (2001) Ethnicity influences morphine pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 70:351-361.
5. Coffman BL, King CD, Rios GR, and Tephly TR (1998) The glucuronidation of opioids, other xenobiotics and androgens by human UGT2B7Y(268) and UGT2B7H(268). Drug Metab Dispos 26:73-77.
6. Coffman B, Rios G, King C, and Tephly T (1997) Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab Dispos 25:1-4.
7. Court MH, Duan SX, Guillemette C, Journault K, Krishnaswamy S, Von Moltke LL, and Greenblatt DJ (2002) Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases (UGTs): S-oxazepam is glucuronidated by UGT2B15, while Roxazepam is glucuronidated by UGT2B7 and UGT1A9. Drug Metab Dispos 30:1257-1265.
8. Court MH and Greenblatt DJ (1997a) Biochemical basis for deficient paracetamol glucuronidation in cats: an interspecies comparison of enzyme constraint in liver microsomes. J Pharm Pharmacol 49:446-449.
9. Court MH and Greenblatt DJ (1997b) Molecular basis for deficient acetaminophen glucuronidation in cats. An interspecies comparison of enzyme kinetics in liver microsomes. Biochem Pharmacol 53:1041-1047.
10. Dehal SS, Gange PV, Crespi CL, and Patten CJ (2001) Characterization of a probe substrate and an inhibitor of UDP-glucuronosyltransferase 1A4 activity in human liver microsomes and cDNA-expressed UGT-enzymes (Abstract). Drug Metab Rev 33:162.
11. Ebner T and Burchell B (1993) Substrate specificities of two stably expressed human liver UDP-glucuronosyltransferases of the UGT1 gene family. Drug Metab Dispos 21:50-55.
12. Fisher MB, Vandenbranden M, Findlay K, Burchell B, Thummel KE, Hall SD, and Wrighton SA (2000) Tissue distribution and interindividual variation in human UDP-glucuronosyltransferase activity: relationship between UGT1A1 promoter genotype and variability in a liver bank. Pharmacogenetics 10:727-739.
13. Green MD, King CD, Mojarrabi B, Mackenzie PI, and Tephly TR (1998) Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3. Drug Metab Dispos 26:507-512.
14. Haumont M, Magdalou J, Lafaurie C, Ziegler JM, Siest G, and Colin JN (1990) Phenobarbital inducible UDP-glucuronosyltransferase is responsible for glucuronidation of 3′-azido-3′-deoxythymidine: characterization of the enzyme in human and rat liver microsomes. Arch Biochem Biophys 281:264-270.
15. Holthe M, Klepstad P, Zahlsen K, Borchgrevink PC, Hagen L, Dale O, Kaasa S, Krokan HE, and Skorpen F (2002) Morphine glucuronide-to-morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A1*28 polymorphisms in cancer patients on chronic morphine therapy. Eur J Clin Pharmacol 58:353-356.
16. Innocenti F, Iyer L, Ramirez J, Green MD, and Ratain MJ (2001) Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7. Drug Metab Dispos 29:686-692.
17. Jin C, Miners J, Lillywhite K, and Mackenzie P (1993) Complementary deoxyribonucleic acid cloning and expression of a human liver uridine diphosphate-glucuronosyltransferase glucuronidating carboxylic acid-containing drugs. J Pharmacol Exp Ther 264:475-479.
18. Krishnaswamy S, Duan SX, von Moltke LL, Greenblatt DJ, and Court MH (2003a) Validation of serotonin (5-hydroxtryptamine) as an in vitro substrate probe for human UDP-glucuronosyltransferase (UGT) 1A6. Drug Metab Dispos 31:133-139.
19. Krishnaswamy S, Duan SX, Von Moltke LL, Greenblatt DJ, Sudmeier JL, Bachovchin WW, and Court MH (2003b) Serotonin (5-hydroxytryptamine) glucuronidation in vitro: assay development, human liver microsome activities and species differences. Xenobiotica 33:169-180.
20. Levesque E, Beaulieu M, Hum DW, and Belanger A (1999) Characterization and substrate specificity of UGT2B4 (E458): a UDP-glucuronosyltransferase encoded by a polymorphic gene. Pharmacogenetics 9:207-216.
21. McLure JA, Miners JO, and Birkett DJ (2000) Nonspecific binding of drugs to human liver microsomes. Br J Clin Pharmacol 49:453-461.
22. Miners JO, Lillywhite KJ, and Birkett DJ (1988) In vitro evidence for the involvement of at least two forms of human liver UDP-glucuronosyltransferase in morphine 3-glucuronidation. Biochem Pharmacol 37:2839-2845.
23. Patten CJ, Code EL, Dehal SS, Gange PV, and Crespi CL (2001) Analysis of UGT enzyme levels in human liver microsomes using form specific anti-peptide antibodies, probe substrate activities and recombinant UGT enzymes (Abstract). Drug Metab Rev 33:165.
24. Rajaonarison JF, Lacarelle B, De Sousa G, Catalin J, and Rahmani R (1991) In vitro glucuronidation of 3′-azido-3′-deoxythymidine by human liver. Role of UDP-glucuronosyltransferase 2 form. Drug Metab Dispos 19:809-815.
25. Resetar A, Minick D, and Spector T (1991) Glucuronidation of 3′-azido-3′-deoxythymidine catalyzed by human liver UDP-glucuronosyltransferase. Significance of nucleoside hydrophobicity and inhibition by xenobiotics. Biochem Pharmacol 42:559-568.
26. Samokyszyn VM, Gall WE, Zawada G, Freyaldenhoven MA, Chen G, Mackenzie PI, Tephly TR, and Radominska-Pandya A (2000) 4-Hydroxyretinoic acid, a novel substrate for human liver microsomal UDP-glucuronosyltransferase(s) and recombinant UGT2B7. J Biol Chem 275:6908-6914.
27. Soars MG, Burchell B, and Riley RJ (2002) In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance. J Pharmacol Exp Ther 301:382-390.
28. Turgeon D, Carrier JS, Levesque E, Hum DW, and Belanger A (2001) Relative enzymatic activity, protein stability and tissue distribution of human steroid-metabolizing UGT2B subfamily members. Endocrinology 142:778-787.
29. Venkatakrishnan K, von Moltke LL, and Greenblatt DJ (2001) Human drug metabolism and the cytochromes P450: application and relevance of in vitro models. J Clin Pharmacol 41:1149-1179.
30. Venkatakrishnan K, von Moltke LL, Obach RS, and Greenblatt DJ (2000) Microsomal binding of amitriptyline: effect on estimation of enzyme kinetic parameters in vitro. J Pharmacol Exp Ther 293:343-350.
31. Yao C, Kunze KL, Kharasch ED, Wang Y, Trager WF, Ragueneau I, and Levy RH (2001) Fluvoxamine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2. Clin Pharmacol Ther 70:415-424.
32. Yao C, Kunze KL, Trager WF, Kharasch ED, and Levy RH (2003) Comparison of in vitro and in vivo inhibition potencies of fluvoxamine toward CYP2C19. Drug Metab Dispos 31:565-571.
33. Yue Q, von Bahr C, Odar-Cederlof I, and Sawe J (1990) Glucuronidation of codeine and morphine in human liver and kidney microsomes: effect of inhibitors. Pharmacol Toxicol 66:221-226.